Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on January 30, 2026 for the New Drug Application (NDA)… Read More
New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test
Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from its Phase 2b clinical trial (LT3001-202) evaluating LT3001 (intravenous Odatroltide) in patients with acute ischemic stroke.
The council unites leading scientists, clinicians, and advocates to ensure that cutting-edge research and lived experience together shape the future of mental health care.
Le Bonheur Children’s Hospital and the University of Tennessee Health Science Center (UTHSC) are proud to announce the appointment of Jason S. Frischer, MD, as Surgeon-in-Chief and Chief of Pediatric Surgery.
This Grant will Advance the Company’s Preclinical Research to Demonstrate an Improvement to the Current Standard of Care for Treating Vertebral Compression Fractures
Changes are coming to a special visa that allows skilled foreign workers into the U.S., as a $100,000 fee introduced by President Donald Trump is being implemented.
The NCPDP Foundation is pleased to announce the successful completion of a study conducted by the University of Tennessee Health Science Center, College of Pharmacy.
